ASP2802 / Astellas - LARVOL DELTA

Astellas calls it quits on early-stage lymphoma CAR-T following pipeline review (FierceBiotech) - "Now, following a review of its pipeline, the Japan-based drugmaker has jettisoned an early CAR-T prospect leveraging technology from its subsidiary Xyphos...The asset in question, an autologous CAR-T dubbed ASP2802 aimed at CD20-positive B-cell lymphomas, had been undergoing a phase 1 trial to determine a suitable dose for further studies as well as the candidate’s tolerability and safety. But an Astellas spokesperson confirmed to Fierce Biotech that 'as a result of our prioritization efforts, we have made the difficult decision to terminate ASP2802.'....They also noted that the work done on ASP2802 has yielded 'important progress' and 'drug development knowledge' that will benefit the company’s efforts in other disease areas."

Discontinued • Trial status • B Cell Lymphoma • Lymphoma

A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas (clinicaltrials.gov) - P1 | N=1 | Terminated | Sponsor: Astellas Pharma Global Development, Inc. | N=21 ➔ 1 | Trial completion date: Aug 2031 ➔ Dec 2024 | Initiation date: Apr 2024 ➔ Sep 2024 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2026 ➔ Dec 2024; The termination of the study was a business decision made by the sponsor.

Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Trial termination • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Trial completion date: May 2031 ➔ Aug 2031 | Trial primary completion date: Mar 2026 ➔ Jun 2026

Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas (clinicaltrials.gov) - P1 | N=21 | Not yet recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Trial primary completion date: May 2031 ➔ Mar 2026

Trial primary completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas (clinicaltrials.gov) - P1 | N=21 | Not yet recruiting | Sponsor: Astellas Pharma Global Development, Inc.

New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology